5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy

Immunology and Cell Biology

Volumn 84, Issue 4, 2006, Pages 383-389

  Matthews, Kate E ^a   Hermans, Ian F ^a   Roberts, Joanna M ^a   Ching, Lai Ming ^b   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

5,6 dimethylxanthenone 4 acetic acid (DMXAA); CD8+ T cell; Dendritic cell (DC); Immunotherapy; TNF

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; COLLAPSE; CONTROLLED STUDY; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOTHERAPY; LUNG CARCINOMA; MOUSE; NONHUMAN; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG SYNERGISM; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; XANTHONES;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 33745067784     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2006.01448.x     Document Type: Article

References (41)

1. Mayordomo JI Zorina T Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995 1 : 1297 302.
2. Hermans IF Daish A Moroni-Rawson P Ronchese F. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol. Immunother. 1997 44 : 341 7.
3. Lash CJ Li AE Rutland M Baguley BC Zwi LJ Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer. 1998 78 : 439 45.
4. Zwi LJ Baguley BC Gavin JB Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res. 1994 6 : 79 85.
5. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003 4 : 141 8.
6. Ching LM Cao Z Kieda C Zwain S Jameson MB Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4- acetic acid. Br. J. Cancer 2002 86 : 1937 42.
7. Siim BG Laux WT Rutland MD Palmer BN Wilson WR. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2, 2′-(1,4-diaminobutane)bis(2- methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res. 2000 60 : 4582 8.
8. Ching LM Goldsmith D Joseph WR Korner H Sedgwick JD Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 1999 59 : 3304 307.
9. Joseph WR Cao Z Mountjoy KG Marshall ES Baguley BC Ching LM. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999 59 : 633 8.
10. Zhao L Ching LM Kestell P Baguley BC. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer 2002 87 : 465 70.
11. Perera PY Barber SA Ching LM Vogel SN. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J. Immunol. 1994 153 : 4684 93.
12. Pang JH Cao Z Joseph WR Baguley BC Ching LM. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur. J. Cancer 1998 34 : 1282 9.
13. Tak PP Taylor PC Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 39 : 1077 81.
14. Thornhill MH Wellicome SM Mahiouz DL Lanchbury JS Kyan-Aung U Haskard DO. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J. Immunol. 1991 146 : 592 8.
15. Franitza S Hershkoviz R Kam N et al. TNF-alpha associated with extracellular matrix fibronectin provides a stop signal for chemotactically migrating T cells. J. Immunol. 2000 165 : 2738 47.
16. Homey B Alenius H Muller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 2002 8 : 157 65.
17. Mackay F Loetscher H Stueber D Gehr G Lesslauer W. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med. 1993 177 : 1277 86.
18. Osborn L Hession C Tizard R et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989 59 : 1203 11.
19. Carlos TM Schwartz BR Kovach NL et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990 76 : 965 70.
20. Bibby MC Phillips RM Double JA Pratesi G. Anti-tumour activity of flavone acetic acid (NSC 347512) in mice-influence of immune status. Br. J. Cancer 1991 63 : 57 62.
21. Ching LM Joseph WR Baguley BC. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br. J. Cancer 1992 66 : 128 30.
22. Pratesi G Rodolfo M Rovetta G Parmiani G. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur. J. Cancer 1990 26 : 1079 83.
23. Jassar AS Suzuki E Kapoor V et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005 65 : 11 752 61.
24. Hermans IF Daish A Yang J Ritchie DS Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res. 1998 58 : 3909 17.
25. Pircher H Burki K Lang R Hengartner H Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989 342 : 559 61.
26. Garrigan K Moroni-Rawson P McMurray C et al. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood 1996 88 : 3508 12.
27. Kemp RA Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J. Immunol. 2001 167 : 6497 502.
28. Finlay GJ Ching LM Wilson WR Baguley BC. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. J. Natl Cancer Inst. 1987 79 : 291 6.
29. Banchereau J Briere F Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000 18 : 767 811.
30. Fong L Engleman EG. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 2000 18 : 245 73.
31. Philpott M Baguley BC Ching LM. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4- acetic acid. Cancer Chemother. Pharmacol. 1995 36 : 143 8.
32. Cumberbatch M Kimber I. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. Immunology 1992 75 : 257 63.
33. Cumberbatch M Dearman RJ Kimber I. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology 1997 92 : 388 95.
34. Norbury CC Basta S Donohue KB et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 2004 304 : 1318 21.
35. Wolkers MC Brouwenstijn N Bakker AH Toebes M Schumacher TN. Antigen bias in T cell cross-priming. Science 2004 304 : 1314 17.
36. Neijssen J Herberts C Drijfhout JW Reits E Janssen L Neefjes J. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005 434 : 83 8.
37. Binder RJ and Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat. Immunol. 2005 6 : 593 9.
38. Morel S Levy F Burlet-Schiltz O et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000 12 : 107 17.
39. Wiltrout RH Boyd MR Back TC Salup RR Arthur JA Hornung RL. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J. Immunol. 1988 140 : 3261 5.
40. Hornung RL Back TC Zaharko DS Urba WJ Longo DL Wiltrout RH. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. J. Immunol. 1988 141 : 3671 9.
41. Kanwar JR Kanwar RK Pandey S Ching LM Krissansen GW. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res. 2001 61 : 1948 56.